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E-mail address: ana-maria.cuervo@einstein.yu.eduChaperone-mediated autophagy (CMA) is a lysosomal pathway that participates in the degradation
of cytosolic proteins. CMA is activated by starvation and in response to stressors that result in pro-
tein damage. The selectivity intrinsic to CMA allows for removal of damaged proteins without dis-
turbing nearby functional ones. CMA works in a coordinated manner with other autophagic
pathways, which can compensate for each other. Interest in CMA has recently grown because of
the connections established between this autophagic pathway and human pathologies. Here we
review the unique properties of CMA compared to other autophagic pathways and its relevance in
health and disease.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Renewal of intracellular proteins through their continuous syn-
thesis and degradation assures proper function of the cellular pro-
teome [1,2]. Protein degradation is a conservative cellular process
that allows recycling of cellular building blocks (amino acids)
and at the same time provides a mechanism for protein quality
control. Two main systems participate in intracellular proteolysis:
the proteasome and the lysosome or autophagy [1,2]. While the
proteasome is, for the most part, responsible for a rapid protein
turnover, lysosomes preferentially degrade proteins with longer
half-lives along with other intracellular components, such as whole
organelles, lipid deposits, proteinaceous inclusions and aggregates,
and even pathogens (once they reach the cytosolic compartment).
Three different pathways deliver cytosolic cargo to the lysosome in
mammalian cells: microautophagy, macroautophagy, and chaper-
one-mediated autophagy (CMA) [3]. In contrast to micro- and mac-
roautophagy, where whole regions of the cytosol are sequestered
and delivered to lysosomes, CMA targets single cytosolic proteins
to the lysosomal surface and mediates their one-by-one transloca-
tion across the lysosomal membrane for degradation [4,5]. The
selectivity of CMA is determined by the recognition of a speciﬁc
amino acid motif in the substrate protein by a cytosolic chaper-
one/co-chaperone complex [6]. Despite the clear differenceschemical Societies. Published by E
evelopmental and Molecular
in College of Medicine, 1300
18 430 8975.
(A.M. Cuervo).among autophagic pathways, growing evidence supports that they
function in an interdependent manner and can partially compen-
sate for each other’s dysfunction [7–9]. Like macroautophagy,
CMA can be a provider of energy when nutrients are scarce, and
it participates in protein quality control, as it can selectively target
damaged proteins for degradation. CMA is thus an important com-
ponent of the cellular response to different types of stressors [4,5].
Consequently, CMA dysfunction and its decreased activity with age
have been proposed to contribute to the alterations in cellular
homeostasis associated with severe pathologies, such as some neu-
rodegenerative diseases, kidney pathologies and metabolic disor-
ders, and to the diminished ability of old organisms to respond
to stress. In this review, we ﬁrst describe the unique characteris-
tics, molecular effectors and regulators of this pathway compared
to other autophagic pathways, and then comment on the cellular
consequences of CMA failure and the recently described involve-
ment of CMA dysfunction in human pathologies and in aging.2. Molecular components of CMA
In contrast to the ‘‘in bulk” sequestration of portions of cytosol
that include complete organelles observed in other autophagic
pathways, CMA is a highly selective autophagic mechanism that
targets only speciﬁc soluble proteins for lysosomal breakdown
[4,5]. Two main characteristics that differentiate CMA from other
autophagic processes are the fact that individual proteins can be
separately selected for degradation through this pathway, and
the need for this autophagic cargo to undergo complete unfoldinglsevier B.V. All rights reserved.
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ment stems from the fact that CMA substrates are translocated
across the lysosomal membrane, rather than engulfed or seques-
tered through vesicular structures, as described for other autopha-
gic pathways. Selectivity and direct translocation across the
lysosomal membrane are achieved in CMA by the participation of
two major protein complexes that constitute the essential machin-
ery of this autophagic pathway: a subset of cytosolic chaperones
and co-chaperones that recognize cargo [10] and a group of lyso-
somal proteins that sit on both sides of the lysosomal membrane
and mediate cargo translocation [11–14] (Fig. 1a).
2.1. The cargo recognition complex
All CMA substrates contain in their amino acid sequence a motif
biochemically related to the pentapeptide KFERQ required for their
selective recognition by the CMA cytosolic chaperone complex [6].
Sequence analysis revealed that 30% of cytosolic proteins carry
these type of motifs making them putative CMA substrates [15].
However, very often, many of these potential CMA substrates also
carry targeting signals for other proteolytic systems. This multi-
plicity of degradative pathways for a single protein, initially per-
ceived as an exception, has become a common feature of many
intracellular proteins. Although the current challenge resides in
understanding how these degradative signals are prioritized, grow-Fig. 1. Chaperone-mediated autophagy, basic components and regulation. (a) Steps
on CMA. The two essential components of CMA are the cargo recognition complex
(in the cytosol) and the cargo translocation complex (at the lysosomal membrane).
The CMA-targeting motif (KFERQ-like) in the substrate protein is recognized by
cytosolic hsc70, main component of the cargo recognition complex, and this
delivers it to the surface of the lysosomes where it binds to LAMP-2A. This single-
span membrane protein and a luminal form of hsc70 (lys-hsc70) are the major
components of the cargo translocation complex. Whereas substrate proteins bind to
monomeric forms of LAMP-2A, organization of LAMP-2A into high order multimeric
complexes is required for substrate translocation. Once in the lumen the substrate
is rapidly degraded. (b and c) Regulation of CMA. CMA activity is directly dependent
on the amount of LAMP-2A molecules available at the lysosomal membrane. Levels
of LAMP-2A are regulated by de novo synthesis (not depicted here), through changes
in their regulated Cathepsin A-dependent degradation at the lysosomal membrane
(b) and by the direct insertion of a luminal resident pool of LAMP-2A into the
lysosomal membrane (c).ing evidence supports the notion that each protein’s fate likely de-
pends on factors such as cellular conditions, activity and
accessibility of the different proteolytic systems, and reasons for
its degradation (i.e. damage vs. as further supply of amino acids).
Consequently, the presence of a CMA-targeting motif is necessary
but not sufﬁcient to determine its degradation through this auto-
phagic pathway. In fact, the targeting motif needs to be exposed
for recognition by the heat shock cognate protein of 70 kDa,
hsc70, a cytosolic member of the hsp70 family of chaperones,
and the main component of the CMA cargo recognition complex
[10]. As for many other cellular processes involving chaperones,
the interaction of hsc70 with the substrate proteins is modulated
by co-chaperones that determine the kinetics of substrate bind-
ing/release [16]. Once the substrate-chaperone complex is formed,
it is rapidly targeted toward the CMA translocation complex at the
lysosomal membrane, by still unknown mechanisms (Fig. 1a).
2.2. The CMA translocation complex
The only known lysosomal transmembrane protein involved in
CMA substrate binding and uptake is the lysosome-associated
membrane protein type 2A (LAMP-2A), a splice variant of the
lamp2 gene [13]. This single-span membrane protein participates
in both substrate binding to the lysosomal membrane and its
translocation into the lumen. Studies, using blocking antibodies
and synthetic peptide homologues to the 12 amino acid tail,
which LAMP-2A exposes at the cytosolic side of the lysosomal
membrane, revealed that CMA substrates bind to a positive
charged stretch of amino acids in this tail [17,18]. Binding of sub-
strates to the LAMP-2A tail occurs while still in their native con-
ﬁrmation, but complete substrate unfolding is required for a
successful transport [19]. Although the exact mechanism leading
to substrate unfolding is currently unknown, it has been proposed
that some of the components of the chaperone/co-chaperone tar-
geting complex may also contribute to substrate unfolding once at
the lysosomal membrane [16]. The minimal components required
for translocation of CMA substrates across the lysosomal mem-
brane have been identiﬁed as LAMP-2A and a form of hsc70 that
resides in the lysosomal lumen (lys-hsc70) [11,20], however, none
of these proteins display the membrane multispan properties typ-
ical of most transporter systems. A longstanding search for a
CMA-related translocon-like protein has failed to identify a ‘‘sta-
ble” channel or pore at the lysosomal membrane. Instead, organi-
zation of LAMP-2A molecules at the lysosomal membrane with
other yet unknown proteins to form a 700 kDa molecular weight
protein complex is necessary for delivery of CMA substrate pro-
teins to the lysosomal lumen [14] (Fig. 1a). Both lys-hsc70 and a
recently identiﬁed lysosome-associated hsp90 are required for
stabilization, assembly and disassembly of the LAMP-2A-enriched
multimeric complexes [14]. Once the unfolded substrate reaches
the lysosome lumen, it is degraded within minutes by the wide
array of luminal proteases. CMA activity in a given cell is directly
dependent on the lysosomal levels of these two components,
LAMP-2A at the lysosomal membrane and lys-hsc70 in the lyso-
somal lumen [12,21,22]. In fact, lysosomes lacking lumenal
hsc70, despite containing LAMP-2A in the membrane, are unable
to perform CMA [23]. Likewise, if LAMP-2A is knocked down,
the presence of hsc70 in the lysosomal lumen is not sufﬁcient
to achieve CMA [7]. In fact, changes in levels of LAMP-2A at the
lysosomal membrane (through modiﬁcations in its de novo syn-
thesis or degradation in this compartment) directly determine
rates of CMA in most cells [21]. In contrast, conditions in which
levels of the cytosolic targeting complex become limiting have
not been described until date, maybe due to the multiplicity of
functions in addition to CMA that the chaperones constituent of
these complexes are involved in.
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Selective targeting of cytosolic proteins for degradation through
CMA contributes to both cellular ‘‘housekeeping” and to the cellu-
lar ability to respond to stress [4,5]. Although initially identiﬁed as
a stress-induced pathway, it has become evident that certain level
of CMA activity is detectable in all cells even under basal condi-
tions. Basal CMA activity varies from cell type to cell type and
may contribute to selective degradation of certain regulatory pro-
teins and to specialized functions. For example, CMA has been pro-
posed to contribute to delivering of speciﬁc intracellular antigens
to the lysosomal compartment for processing and presentation
upon binding to MHC class II molecules [24]. Activation of CMA oc-
curs in response to two main cellular events: when an alternative
source of amino acids and energy is needed, or when return to
homeostasis requires removal of damaged or malfunctioning intra-
cellular proteins. During prolonged nutritional deprivation, CMA
can selectively recycle the constituent amino acids of no longer
needed proteins, in order to maintain synthesis of essential pro-
teins and to provide an additional fueling source until access to
nutrients is regained [22]. Conditions that promote accumulation
of misfolded or oxidized proteins also often induce activation of
CMA as part of the quality control cellular system to eliminate
these dysfunctional proteins [25].
Activation of CMA during starvation is paralleled by an increase
of the levels of LAMP-2A at the lysosomal membrane and of lumi-
nal lys-hsc70 [21,23]. LAMP-2A is present in a large subset of lyso-
somes, whereas lys-hsc70 can only be detected in a discrete pool of
cellular lysosomes – those able to perform CMA [23]. However, the
percentage of CMA active lysosomes is not ﬁxed but changes to
accommodate cellular requirements. Thus, although, for example,
in liver under basal conditions only 20–30% of lysosomes contain
lys-hsc70, as starvation persists, lys-hsc70 can be detected in up
to 80% of lysosomes [23]. Lysosome levels of hsc70 are modulated
through changes in the stability of this luminal chaperone, which
are tightly dependent on lysosomal pH [23]. In hsc70-containing
lysosomes, availability and dynamics of the LAMP-2A receptor at
the lysosomal membrane become the rate-limiting step in CMA
[21]. The levels of LAMP-2A are regulated differently, depending
on the type of the intracellular environment and the type of stimuli
inducing CMA activation. The increase in LAMP-2A levels at the
lysosomal membrane observed during prolonged nutrient depriva-
tion does not require de novo synthesis but instead is attained by
decreasing the rates of degradation of this receptor at the lyso-
somal membrane [21,26]. LAMP-2A degradation is a tightly regu-
lated process that involves the recruitment of this protein to
discrete lipid microdomains on the lysosomal membrane and a
sequential cleavage by two proteases in these regions [26]
(Fig. 1b). Conditions leading to activation of CMA decrease LAMP-
2A degradation by preventing its association to the lipid-rich
microdomains and favoring its organization into the multimeric
translocation complexes [27]. Further increase of LAMP-2A mole-
cules at the lysosomal membrane is often attained through recruit-
ment toward this compartment of the pool of LAMP-2A molecules
normally present in the lysosomal lumen [21] (Fig. 1c). In contrast,
activation of CMA during mild oxidative stress is mainly achieved
by increasing de novo synthesis of LAMP-2A [25]. The actual signal-
ing mechanisms that modulate this transcriptional activation of
LAMP-2A are still undetermined. It is likely that activation of
CMA in response to different intra- and extracellular stressors is
regulated through separate signaling cascades.
Recent studies also support that CMA activity is directly inter-
dependent with the activity of other autophagic pathways and, in
particular, macroautophagy. Both macroautophagy and CMA are
often upregulated in response to similar stimuli (nutritional depri-vation, oxidative stress, etc.) but with a different time-course of
activation. In the case of nutritional deprivation, for example, in
cells, such as ﬁbroblasts and hepatocytes, activation of macroauto-
phagy occurs ﬁrst (during the ﬁrst 4–6 h of starvation), whereas
CMA activation does not occur until macroautophagic activity
starts to decrease (about 10 h into starvation) [7,22,28]. The exis-
tence of a close relationship between both autophagic pathways
has been further supported by the fact that experimental blockage
of one of them results in compensatory upregulation of the other,
thus revealing that the two autophagic pathways cross-talk in both
directions. Chronic blockage of CMA in cultured cells via lentiviral
knock-down of LAMP-2A leads to constitutive upregulation of
macroautophagy [7]. However, both pathways are not completely
redundant, and even though basal cellular homeostasis is pre-
served in these cells through this compensatory activation of mac-
roautophagy, they become highly sensitive to stressors that induce
CMA, such as oxidative stress and exposure to UV light [7]. Like-
wise, blockage of macroautophagy in different cell types leads to
constitutive activation of CMA [8], which confers higher resistance
to oxidative stress but makes them vulnerable to other stressors
where engagement of macroautophagy is essential for cell survival
[9]. The molecular mechanisms that modulate cross-talk between
macroautophagy and CMA are currently under investigation. Fur-
ther studies are necessary to determine whether this cross-talk
also transcends to other proteolytic systems, such as the ubiqui-
tin/proteasome system. Acute and chronic blockages of the
proteasome have been shown to upregulate or deregulate macro-
autophagy, respectively [29,30], but the effect of these interven-
tions on CMA is unknown. However, the fact that during the
early stages of CMA inhibition some proteosomal proteolytic activ-
ities are impaired [31] and that speciﬁc subunits of the proteasome
undergo selective degradation via CMA [32], provide evidence that
cross-talk between these two proteolytic pathways may also occur.
For example, CMA degradation of proteasome subunits could be
behind the observed decrease in proteasome activity during pro-
longed nutrient deprivation that leads to the stabilization of
important regulatory proteins under these conditions.
Besides activation of CMA to selectively degrade a pool of cyto-
solic proteins to provide cellular fueling during prolonged starva-
tion or to selectively eliminate damaged protein molecules, CMA
also contributes to modulating cellular functions directly depen-
dent on certain CMA substrates. Thus, for example, the proposed
specialized function of CMA in antigen presentation in professional
antigen presenting cells, or a recently identiﬁed role of CMA as
modulator of neuronal survival through the selective degradation
of the transcription factor myocyte enhancer factor D [33]. Further
characterization of CMA substrate proteins may reveal involve-
ment of CMA in other fundamental cellular functions.
4. CMA and pathology
Our current understanding of the involvement of CMA in differ-
ent aspects of cellular physiology, the identiﬁcation of a close
interrelation between CMA activity and that of other proteolytic
pathways, as well as the discovery of new CMA substrates, have
all contributed to an increased awareness of the role of CMA in cer-
tain pathologies. In some of these conditions, a primary CMA defect
is likely to be behind the pathogenesis, whereas in others, changes
in CMA activity are secondary to the main defect but add up to the
pathology and may contribute to the course of the disease.
4.1. Lysosomal storage diseases
Altered CMA in this group of diseases is often secondary to the
primary impairment in the lysosomal compartment common to all
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disorders that lead to improper degradation of certain substrates in
lysosomes. Although the causes for defective lysosomal activity
vary (they include mutations in speciﬁc enzymes or disrupted traf-
ﬁcking of these enzymes to lysosomes, etc.), the consequences are
similar: abnormal accumulation of the substrate leads to the
expansion of the lysosomal compartment, dysfunction of other
lysosomal processes, eventual leakage of lysosomal contents, and
often cell death [34]. This global lysosomal dysfunction is thus
likely to disrupt CMA activity along with other autophagic path-
ways. However, there are also several LSDs in which defective
CMA activity may precede global failure of the lysosomal system.
Abnormal CMA upregulation has been observed in galactosialido-
sis, a disorder resulting from defective function of protective
protein/Cathepsin A, a lysosomal protein required for proper lyso-
somal targeting of two major glycosidases. The observed changes
in CMA are independent of the defect in these glycosidases but re-
sult from the fact that Cathepsin A is one of the two proteases re-
quired for the regulated degradation of LAMP-2A [26]. The
abnormally high levels of LAMP-2A, observed in galactosialidosis,
and the consequent increase in CMA activity, could be normalized
when Cathepsin A levels were restored in culture by overexpres-
sion or in galactosialidosis mouse models by gene therapy [26].
A primary defect in CMA has been proposed to contribute to
pathogenesis of mucolipidosis type IV (MLIV) [35]. The transient
receptor potential mucolipin 1 (TRPML1), mutated in this disorder,
has been found to associate with hsc70 and hsp40 at the lysosomal
membrane and might be a novel regulator of the CMA transloca-
tion channel. Fibroblasts from the MLIV patients have decreased
CMA activity and, consequently, increased levels of oxidized pro-
teins [35].
Changes in CMA are also likely to occur in Danon disease, a lyso-
somal glycogen storage disorder with normal acid maltase activity,
recently linked to mutation in the lamp2 gene [36]. However, due
to the multiplicity of functions of the different LAMP-2 protein
variants and the poor condition of the lysosomal system in these
patients (defects in lysosomal biogenesis due to altered intracellu-
lar trafﬁcking of essential lysosomal enzymes have been de-
scribed), further studies are required to dissect whether CMA
activity is altered in these patients.
4.2. Nephropathies
As described in the previous section, recent ﬁndings have linked
CMA activity to tubular kidney cell growth through the degrada-
tion of Pax2 [37]. Hypertrophic cellular growth can be achieved
when protein synthesis overweighs protein degradation. In nephr-
opathies like diabetes, acidosis, and chronic kidney disease, the
kidney undergoes hypertrophy. Recent studies have demonstrated
that CMA is inhibited in such pathologies, thus contributing to a
decrease in proteolysis along with a progressive increase in the
cytosolic pool of CMA substrate proteins [38]. Among them, the in-
creased levels of the transcription factor Pax2 may contribute to
maintenance of the hypertrophic state through upregulation of
tubular cell growth [37].
4.3. Neurodegenerative disorders
The hallmark of most neurodegenerative disorders is the accu-
mulation of pathogenic proteins that often organize into intra- or
extracellular aggregates [39]. Alterations in the cellular quality
control mechanisms have been proposed to contribute to the neu-
ronal inability to handle the pathogenic proteins. Dysfunction of
macroautophagy, often revealed as a marked increase in the num-
ber of autophagic vacuoles in the affected neurons, and the conse-
quent loss in the autophagic cytoprotective effect, has beendescribed in a growing number of neurodegenerative diseases.
However, alteration of macroautophagy is not necessarily the pri-
mary or unique autophagic defect in many of these diseases. Many
of the pathogenic proteins involved in neurodegenerative disor-
ders, such as APP and Tau in Alzheimer’s (AD), a-synuclein, Parkin,
UCH-L1, Pink-1, DJ-1 and LRRK2 in Parkinson’s (PD) and huntingtin
in Huntington’s (HD) disease, contain KFERQ motifs in their amino
acid sequences and could be consequently putative CMA sub-
strates. Below, we review the recent ﬁndings regarding the
involvement of CMA in the pathogenesis of these disorders.
Pathogenic forms of a-synuclein were the ﬁrst ones for which a
connection with CMA dysfunction was established [40]. Wild-type
a-synuclein can indeed be translocated through the lysosomal
membrane to undergo degradation via CMA [40] (Fig. 2a). How-
ever, although mutant forms of a-synuclein, described in familial
forms of PD, interact with the cytosolic chaperone complex and
bind to LAMP-2A with higher binding afﬁnity than the wild-type
protein, their translocation is inefﬁcient and their association to
the membrane ends up ‘‘clogging” the CMA translocation channels.
(Fig. 2b) This inhibitory effect on CMA activity contributes to
neurotoxicity, as disrupting the CMA-targeting motif in mutant
forms of a-synuclein prevents their delivery to lysosomes and in-
creases cellular viability [40,41]. Not only mutations, but also
post-translational modiﬁcations of a-synuclein could modify
CMA of this protein. Phosphorylation, ubiquitination, nitration
and oxidation have been detected in the a-synuclein that accumu-
lates in cytosolic inclusions in the affected neurons. While these
forms often display reduced CMA, they do not alter degradation
of other CMA substrates [42]. In contrast, dopamine-modiﬁed a-
synuclein clogs the translocation complex and prevents CMA of
other proteins, thus making cells more vulnerable to stressors
[42]. The inhibitory effect of dopamine-modiﬁed a-synuclein on
CMA could be an underlying explanation for the higher rates of
degeneration observed in dopaminergic neurons in PD. Altered
CMA in cells expressing mutant UCH-L1, another PD pathogenic
protein, have also been recently described [43]. Whether the other
PD proteins, containing CMA-targeting motifs, may also contribute
to pathogenesis by inducing CMA dysfunction requires further
investigation.
A recent study has also revealed a previously unknown connec-
tion between CMA and AD through the degradation of Tau. The
amyloidogenic properties of fragments of Tau protein, identiﬁed
in some AD patients, could make them the seeding mechanism
for pathologic aggregate formation. Using an inducible neuronal
tauopathy model, it has been shown that Tau fragmentation initi-
ates in the cytosol, but it is completed at the lysosomal surface
[44]. CMA is the mechanism behind Tau delivery to lysosomes,
but the pathogenic fragment fails to get translocated, remaining
on the lysosomal surface and promoting the formation of Tau olig-
omers – possible precursors of aggregation [44] (Fig. 2b).
In light of the involvement of CMA in the maintenance of cellu-
lar homeostasis and in the response to stress, blockage of CMA in
these pathologies may further contribute to creating a cellular
environment favorable for protein aggregation. Blockage of CMA
and often of the proteasome, which is also a target of the toxic ef-
fect of the pathogenic proteins, leads to the upregulation of macro-
autophagy (Fig. 2b). Activation of macroautophagy under these
conditions helps to maintain cellular homeostasis, by directly
degrading pathogenic protein aggregates and also by reducing
the pool of their soluble cytosolic forms that contribute to aggre-
gate formation. Although it has been proposed that excessive mac-
roautophagy may be detrimental, upregulation of macraoutophagy
in response to CMA dysfunction, at least in cultured cells, has
shown so far to have a protective effect. Thus, inhibition of this
compensatory macroautophagy has been shown to compromise
cell viability [7]. Progression of the disease may be tightly related
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exhaustion – as it becomes often the only functional proteolytic
system- or through an eventual toxic effect of the pathogenic pro-
teins also in this system (Fig. 2c).
In several of these neurodegenerative disorders, interventions
aimed at upregulating macroautophagy are beneﬁcial [45] and
could have therapeutic value. Upregulation of CMA, together with
the elucidation of the mechanism(s) behind the failed lysosomal
translocation of pathogenic synuclein and Tau are also promising
future direction for therapy.
4.4. CMA and other pathologies
Numerous recent studies support the pro- and anti-oncogenic
functions of macroautophagy in cancer cells that could be
exploited for therapeutic purposes [3]. In contrast, a relation be-
tween CMA and cancer biology has not been established yet. Preli-
minary evidence from our group has revealed a constitutive
upregulation of CMA in a large number of cancer cell lines (Kon
and Cuervo, in preparation), suggesting that CMA could be impor-
tant for cancer cell progression and survival. Likewise, extensive
information on the consequences of failed macroautophagy in in-
nate and acquired immunity [46] has prompted the discovery of
alterations of macroautophagy underlying severe immune disor-
ders. However, despite the recently described participation of
CMA in antigen presentation [24], connections between CMA and
diseases of the immune system are yet to be identiﬁed.
5. CMA and aging
Increased half-life of numerous intracellular proteins and accu-
mulation of damaged or altered proteins inside cells are features
common to almost all aging organisms and have been directly
linked to inefﬁciencies in the cellular quality control mechanisms
with age [47]. Alterations in both the ubiquitin-proteasome systemFig. 2. Contribution of CMA dysfunction to pathogenesis in neurodegeneration. Different
primary detrimental effect on CMA activity. Whereas wild-type or unmodiﬁed forms of th
their pathogenic counterparts (brown circles) are delivered to the CMA translocation co
pathogenic proteins often organize into irreversible oligomeric complexes at the lysoso
upregulating macroautophagy, the only proteolytic pathway that can directly degrade p
due to exhaustion or primary damage by the pathogenic proteins – could precipitate prand macroautophagy in different cellular and animal models of
aging have been well reported and could further contribute to
the aggravating effect that aging has in many of the above de-
scribed pathologies. CMA activity also declines with aging in al-
most all tissues analyzed so far, mainly as consequence of
decreased levels of LAMP-2A at the lysosomal membrane [48]. Re-
duced levels of LAMP-2A are not due to transcriptional downregu-
lation or problems in lysosomal targeting of this protein, but
instead originate from age-related changes in the lysosomal mem-
brane that affect lysosomal distribution and turnover of LAMP-2A
and render this protein unstable [49].
Since CMA activity is directly proportional to the amount of
available LAMP-2A receptor at the lysosomal membrane, it is rea-
sonable to hypothesize that the deterioration of this proteolytic
system with age could be reversed by restoring normal levels of
the membrane receptor. In fact, in a recent study using a transgenic
mouse model with an inducible exogenous copy of LAMP-2A (Tet-
off-LAMP-2A mouse), activation of the transgene in liver of old
mice was enough to restore levels of CMA close to those observed
in young mice [50]. The lower levels of oxidized and aggregated
proteins observed in the old transgenic mice, along with their im-
proved response to hepatotoxic stressors and better overall liver
function [50], further support the participation of CMA in cellular
homeostasis and the stress response, and underscores the contri-
bution of reduced CMA activity to the functional decline in old
organisms. Future efforts should be directed to devising interven-
tions that could stabilize LAMP-2A in old cells and hence prevent
the age-dependent decline in the activity of this pathway.
6. Concluding remarks
Although lacking the high capability of other autophagic sys-
tems, CMA has made room for itself in the ﬁeld of protein degrada-
tion due to the high selectivity of this pathway in the degradation
of cytosolic soluble proteins, comparable in many respects to thatpathogenic proteins (a-synuclein and Tau) depicted here, have been shown to have a
ese proteins (green circles) can be targeted and taken up by lysosomes via CMA (a),
mplex at the lysosomal membrane but fail to translocate into the lumen (b). These
mal membrane that further block CMA activity. Cells respond to CMA blockage by
roteinaceous inclusions and aggregates (b). Failure of macroautophagy with time –
ogression of disease (c).
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vances in our understanding on how substrate proteins are tar-
geted to lysosomes and cross the lysosomal membrane via CMA
have offered new ways to manipulate this autophagic process
and further understand its contribution to cell physiology. Contri-
butions to homeostasis maintenance and to the cellular stress re-
sponse are chief among the physiological functions of CMA. The
recent link between CMA dysfunction and severe human patholo-
gies has further increased the interest in this autophagic pathway.
Future studies on CMA should aim to elucidate the molecular com-
ponents of the cross-talk between CMA and other autophagic path-
ways, the speciﬁc roles of chaperones and co-chaperones at the
targeting and translocation complexes and the missing compo-
nents in this last complex. Moreover, future insights into the up-
stream signaling that leads to CMA activation will provide
powerful tools to modulate this pathway for therapeutic purposes.
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